STAT Biotech

Recent stories from STAT Biotech.

STAT Biotech Elizabeth Cooney and Matthew Herper

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

Read at STAT Biotech

STAT Biotech Elizabeth Cooney

STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories

“These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease."

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: New tumor cases show common gene therapy tool can come with risk

New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.

Read at STAT Biotech

STAT Biotech Meghana Keshavan

STAT+: Amgen’s Repatha linked to fewer heart attacks

Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…

Read at STAT Biotech

STAT Biotech Ed Silverman and Jason Mast

STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy

Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.

Read at STAT Biotech

STAT Biotech Meghana Keshavan and Jason Mast

STAT+: A possible comeback for a failed sickle cell gene therapy

Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…

Read at STAT Biotech

STAT Biotech Elizabeth Cooney

STAT+: Beyond statins, one drug lowered heart attack risk by 20%

A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."

Read at STAT Biotech

STAT Biotech Mario Aguilar

STAT+: Medicare delays controversial remote patient monitoring rule to 2029

Despite widespread opposition, Medicare will finalize a controversial proposal that will prevent providers, such as hospitals, from using third parties to deliver remote patient monitoring services.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut

Rasonque, Revolution Medicines' new pancreatic cancer drug, is off to one of the best oncology drug launches in history.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: In China, a flood of controversial clinical trials slows to a trickle

Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.

Read at STAT Biotech

STAT Biotech Margaret Manto

STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill

Sanders could use his role in crafting the FDA funding bill to push for reforms.

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: Ultragenyx cuts staff after another study fails

Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.

Read at STAT Biotech